Compare Inovio Pharmaceuticals Inc (INO) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs T-Mobile Us Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while T-Mobile Us Inc trades at $191.69 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 2371.7× Inovio Pharmaceuticals Inc's market cap, and T-Mobile Us Inc pays a 2.09% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TMUS | |
|---|---|---|
Market Cap | $89.27M | $211.72B |
Sector | Health | Media |
52-Week High | $2.87 | $259.01 |
52-Week Low | $1.05 | $167.65 |
Enterprise Value | $60.28M | $329.42B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
T-Mobile US (TMUS) trades at $195.37, up 1.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $88.3B revenue in 2025, 11.65% net margin, and consistent earnings beats in three of the last four quarters. Recent leadership changes and strategic appointments position TMUS for growth amid competitive pressures from satellite internet providers.
TMUS presents a compelling investment case with 83% analyst buy ratings and $238.40 consensus target, offering 22% upside. However, rising debt levels (39.35% debt-to-asset ratio) and Starlink competition pose significant risks. The stock's current RSI levels suggest potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
